Times They Are A-changing

The two companies will be exhibiting together after Gerresheimer’s December 2024 acquisition of Bormioli.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Patrizia Cavazzoni, director of FDA’s Center for Drug Evaluation and Research, has announced her retirement from the agency.

Posdinemab is the second tau-directed investigational therapy by J&J that has received fast track designation from FDA this year for Alzheimer’s disease.